May 23, 2015
Below are current clinical trials.565 studies in Cancer
(open studies only).
Filter this list of studies by location, status and more.
The purpose of this study is to examine bladder filling for radiation treatment to the prostate, and to evaluate how bladder fullness changes daily during radiation treatment.
This phase I/II trial studies the best dose and side effects of dendritic cell therapy, cryosurgery and pembrolizumab in treating patients with non-Hodgkin lymphoma. Vaccines, such as dendritic cell therapy made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells. Cryosurgery kills cancer cells by freezing them. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Giving dendritic cell therapy, cryosurgery and pembrolizumab may work better at treating non-Hodgkin lymphoma.
This phase II trial studies how well recombinant human papillomavirus nonavalent vaccine works in preventing human papillomavirus-related cancer in adult women after kidney transplant. Vaccines made from peptides of human papillomavirus may help the body build an effective immune response to kill tumor cells. Giving booster vaccinations may make a stronger immune response and prevent or delay the recurrence of cancer.
The purpose of this study is to assess the effectiveness of lenvatinib for treating patients who have pheochromocytoma or paraganglioma that has spread to other places in the body or cannot be removed by surgery. Lenvatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
The purpose of this research study is to see if Atorvastatin(Lipitor) 40 mg by mouth daily decreases the chance of developing heart problems in women who are receiving anthracycline-based chemotherapy for breast cancer.
The objective of this study is to validate internally developed assays for the detection of clinically relevant gene mutations in cfDNA from the peripheral blood of patients with non-small cell lung carcinoma.
Jacksonville, Fla., Rochester, Minn.
This study will include a Phase 1 dose-finding portion (Cohorts A and B) and a four-arm expansion portion. The primary objectives of the study are to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of H3B-8800 administered orally in participants with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), or Chronic Myelomonocytic Leukemia (CMML) and to assess the safety and tolerability of H3B-8800 as a single agent administered orally once daily on a 5 days on/9 days off repeated dosing schedule in 28-day cycles in participants with MDS, AML, or CMML.
Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn.
This randomized phase II trial studies how well Ataxia-telangiectasia and Rad3-related [ATR] kinase inhibitor VX-970 (VX-970) and gemcitabine hydrochloride work compared to standard treatment with gemcitabine hydrochloride alone in treating patients with ovarian, primary peritoneal, or fallopian tube cancer that has come back after a period of improvement (recurrent). ATR kinase inhibitor VX-970 may stop the growth of tumor cells by blocking an enzyme needed for cell growth, and may also help gemcitabine hydrochloride work better. Gemcitabine hydrochloride is a drug used in chemotherapy that works to stop the growth of tumor cells by blocking cells from growing and repairing themselves, causing them to die. It is not yet known whether adding ATR kinase inhibitor VX-970 to standard treatment with gemcitabine hydrochloride is more effective than gemcitabine hydrochloride alone in treating patients with ovarian, primary peritoneal, or fallopian tube cancer.
The purpose of the Pediatric Proton Consortium Registry (PPCR) is to enroll children who have been treated with proton radiation in the United States in order to describe the population that currently receives protons and better evaluate its benefits over other therapies. The data collected from this study will help facilitate research on proton beam radiation therapy and allow for collaborative research. The PPCR will collect demographic and clinical data which many centers that deliver proton radiation therapy already collect in routine operations.
Rochester, Minn., Scottsdale/Phoenix, Ariz., Jacksonville, Fla.
This phase II trial studies how well nivolumab works in treating patients with peripheral T-cell lymphoma that has come back after a period of improvement or that does not respond to treatment. Monoclonal antibodies, such as nivolumab, may block cancer growth in different ways by targeting certain cells.
- Deaths and mortality. Centers for Disease Control and Prevention. http://www.cdc.gov/nchs/fastats/deaths.htm. Accessed April 23, 2015.
- Cancer: All sites. Surveillance Epidemiology and End Results. http://seer.cancer.gov/statfacts/html/all.html. Accessed April 23, 2015.
- Symptoms. National Cancer Institute. http://www.cancer.gov/cancertopics/diagnosis-staging/symptoms. Accessed April 23, 2015.
- Kushi LH, et al. American Cancer Society guidelines on nutrition and physical activity for cancer prevention: Reducing the risk of cancer with healthy food choices and physical activity. CA: A Cancer Journal for Clinicians. 2012;62:30.
- Niederhuber JE, et al., eds. Genetic and epigenetic alterations in cancer. In: Abeloff's Clinical Oncology. 5th ed. Philadelphia, Pa.: Churchill Livingstone Elsevier; 2014. http://www.clinicalkey.com. Accessed April 23, 2015.
- Ulcerative colitis. National Institute of Diabetes and Digestive and Kidney Diseases. http://digestive.niddk.nih.gov/ddiseases/pubs/colitis/index.htm. Accessed April 23, 2015.
- NINDS paraneoplastic syndromes information page. National Institute of Neurological Disorder and Stroke. http://www.ninds.nih.gov/disorders/paraneoplastic/paraneoplastic.htm. Accessed April 23, 2015.
- Deng GE, et al. Evidence-based clinical practice guidelines for integrative oncology: Complementary therapies and botanicals. Journal of the Society for Integrative Oncology. 2009;7:85.
- Taking time: Support for people with cancer. National Cancer Institute. http://cancer.gov/cancertopics/takingtime. Accessed April 23, 2015.
- Moynihan TJ (expert opinion). Mayo Clinic, Rochester, Minn. May 1, 2015.
- Hypercalcemia (high level of calcium in the blood). Merck Manual Home Edition. http://www.merckmanuals.com/home/hormonal-and-metabolic-disorders/electrolyte-balance/hypercalcemia-high-level-of-calcium-in-the-blood. Accessed April 23, 2015.
- What is cancer? National Cancer Institute. http://www.cancer.gov/cancertopics/what-is-cancer. Accessed April 23, 2015.
- Cancer prevention overview (PDQ). National Cancer Institute. http://www.cancer.gov/cancertopics/pdq/prevention/overview/patient/page1/AllPages. Accessed April 23, 2015.
- The genetics of cancer. National Cancer Institute. http://www.cancer.gov/cancertopics/causes-prevention/genetics. Accessed April 23, 2015.
- Understanding cancer risk. Cancer.Net. http://www.cancer.net/navigating-cancer-care/prevention-and-healthy-living/understanding-cancer-risk. Accessed April 23. 2015.
- Cancer screening overview (PDQ). National Cancer Institute. http://www.cancer.gov/cancertopics/pdq/screening/overview/HealthProfessional. Accessed April 23, 2015.
- Diagnosis. National Cancer Institute. http://www.cancer.gov/cancertopics/diagnosis-staging/diagnosis. Accessed April 23, 2015.
- Staging. National Cancer Institute. http://www.cancer.gov/cancertopics/diagnosis-staging/staging. Accessed April 23, 2015.
- Making decisions about cancer treatment. Cancer.Net. http://www.cancer.net/navigating-cancer-care/how-cancer-treated/making-decisions-about-cancer-treatment. Accessed April 23, 2015.
- How cancer is treated. Cancer.Net. http://www.cancer.net/navigating-cancer-care/how-cancer-treated. Accessed April 23, 2015.